Immune Thrombocytopenic Purpura Clinical Trials 2026 — Find Recruiting Studies

About Immune Thrombocytopenic Purpura

Immune thrombocytopenic purpura is an acquired autoimmune disorder in which autoantibodies directed against platelet surface glycoproteins (primarily GPIIb/IIIa and GPIb/IX) accelerate platelet destruction by the reticuloendothelial system and impair megakaryocyte platelet production in the bone marrow. It is classified as newly diagnosed (less than 3 months), persistent (3-12 months), or chronic (greater than 12 months), with the chronic form predominantly affecting adult women. Treatment options include corticosteroids, intravenous immunoglobulin, thrombopoietin receptor agonists, rituximab, and splenectomy, reflecting its heterogeneous pathophysiology.

Common Clinical Features

Thrombocytopenia with platelet count typically below 100,000/uL Easy bruising and purpura Petechiae particularly on the lower extremities Mucosal bleeding including gingival and epistaxis Menorrhagia in women of childbearing age Fatigue independent of anemia Risk of intracranial hemorrhage at very low platelet counts Generally normal white blood cell and red blood cell counts

Clinical Trial Eligibility Tips

What to know before applying to Immune Thrombocytopenic Purpura trials.

Document your ITP phase (newly diagnosed, persistent, or chronic), as most interventional trials target chronic ITP with at least 12 months of disease; bring platelet count trends over time.

Prior treatment history including corticosteroids, IVIG, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonist (TPO-RA) use and response is critical for eligibility in second-line and salvage therapy trials.

Pregnancy status, concurrent autoimmune conditions (SLE, antiphospholipid syndrome), and secondary ITP causes must be excluded for most primary ITP trial enrollment.